Why Traders Flocked to These 10 Stocks on Monday

3. ADMA Biologics, Inc. (NASDAQ:ADMA)

ADMA Biologics soared to a new all-time high on Monday after securing the approval of the Food and Drug Administration (FDA) for its innovative yield enhancement production process.

According to the company, the innovative process has demonstrated an ability to increase production yields by approximately 20 percent from the same starting plasma volume.

Following the announcement, ADMA Biologics, Inc. (NASDAQ:ADMA) touched a new record high of $25.67 at intraday trading before early profit-taking pulled its price slightly lower to end the day just up by 12.12 percent at $24.51 apiece.

“This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond,” said Adam Grossman, president and CEO of ADMA Biologics, Inc. (NASDAQ:ADMA).

“Looking ahead, we are excited to continue to advance our internal R&D platform—further optimizing production capabilities and progressing novel pipeline programs, most notably SG-001, our pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, which exemplifies our commitment to product and process innovation,” he added.